Get the Stockscreener App
1.48
8.82%
0.12
After Hours:
1.48
MAIA Biotechnology Inc stock is traded at $1.48, with a volume of 545.07K.
It is up +8.82% in the last 24 hours and up +49.65% over the past month.
MAIA Biotechnology, Inc., a clinical stage biotechnology company, engages in the discovery, development, and commercialization of therapies targeting cancer. The company's lead product candidate is THIO, a telomere-targeting agent that is in Phase II clinical study to evaluate its activity in patients with non-small cell lung cancer. It is also developing second generation telomere targeting agents. MAIA Biotechnology, Inc. was incorporated in 2018 and is headquartered in Chicago, Illinois.
See More
Previous Close:
$1.36
Open:
$1.41
24h Volume:
545.07K
Relative Volume:
0.78
Market Cap:
$54.81M
Revenue:
-
Net Income/Loss:
$-25.94M
P/E Ratio:
-1.0725
EPS:
-1.38
Net Cash Flow:
$-15.79M
1W Performance:
+28.70%
1M Performance:
+49.65%
6M Performance:
-14.94%
1Y Performance:
-25.63%
1-Day Range:
$1.35
$1.48
1-Week Range:
$1.13
$1.48
52-Week Range:
$0.87
$2.74
MAIA Biotechnology Inc Stock (MAIA) Company Profile
Name
MAIA Biotechnology Inc
Sector
Industry
Phone
312 416 8592
Address
444 West Lake Street, Suite 1700, Chicago
Compare MAIA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MAIA
MAIA Biotechnology Inc
|
1.48 | 50.36M | 0 | -25.94M | -15.79M | -1.38 |
|
VRTX
Vertex Pharmaceuticals Inc
|
462.99 | 116.51B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
783.71 | 82.52B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
400.69 | 52.67B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
849.95 | 52.08B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
177.42 | 37.70B | 447.02M | -1.18B | -906.14M | -6.1812 |
MAIA Biotechnology Inc Stock (MAIA) Latest News
MAIA Biotechnology Board Members Continue to Participate in Private Placement Financings - The Manila Times
Chaouki Steven M buys MAIA Biotechnology shares worth $49999 By Investing.com - Investing.com Australia
Stan Smith buys MAIA Biotechnology shares worth $69,999 By Investing.com - Investing.com Australia
Stan Smith buys MAIA Biotechnology shares worth $69,999 - Investing.com
Chaouki Steven M buys MAIA Biotechnology shares worth $49999 - Investing.com
Louie Ngar Yee buys MAIA Biotechnology (MAIA) shares worth $99999 - Investing.com
Swing Trade: Why hedge funds are buying MAIA Biotechnology Inc stockJuly 2025 Movers & Safe Entry Momentum Stock Tips - moha.gov.vn
Can MAIA Biotechnology Inc. stock double in next 5 yearsPortfolio Gains Report & Capital Efficiency Focused Ideas - DonanımHaber
How MAIA Biotechnology Inc. stock compares to industry benchmarksWeekly Profit Summary & AI Forecasted Entry/Exit Points - Улправда
Can MAIA Biotechnology Inc. stock maintain operating marginsJuly 2025 Intraday Action & Expert Approved Momentum Ideas - Bölüm Sonu Canavarı
Why MAIA Biotechnology Inc. stock is upgraded to buy2025 Valuation Update & Daily Growth Stock Tips - DonanımHaber
MAIA Biotechnology announces $2.25M private placement deal - MSN
MAIA Biotechnology Announces $2.25M Private Placement Deal - TipRanks
MAIA Biotechnology (NYSE American: MAIA) details $2.25M private placement - Stock Titan
MAIA Biotechnology Announces $1.51 Million Private Placement - The Manila Times
MAIA Biotechnology, Inc. announced that it expects to receive $1.289791 million in funding - marketscreener.com
MAIA Biotechnology Earnings Notes - Trefis
MAIA Biotechnology Announces Significant Insider Buying - TipRanks
MAIA Biotechnology, Inc. Announces Key Developments in Cancer Therapy - TradingView — Track All Markets
MAIA Biotechnology (NYSE: MAIA) starts Ateganosine Phase 3 trial and notes insider buying - Stock Titan
MAIA Biotechnology (NYSE American: MAIA) begins Phase 3 NSCLC study of telomere-targeting ateganosine - Stock Titan
MAIA Biotechnology Announces First Patient Dosed in THIO-104 Phase 3 Pivotal Trial Evaluating Ateganosine as Third-Line Treatment for Advanced Non-Small Cell Lung Cancer - Yahoo Finance
MAIA Leadership Continues Insider Buying in 2025 and Trial Data Signals Breakout Potential - Yahoo Finance
MAIA’s Ateganosine Surges Ahead with Breakthrough Momentum as Pivotal Phase 3 Trial Initiates - Yahoo Finance
MAIA Biotechnology Advances NSCLC Treatment with Ateganosine - TipRanks
MAIA Biotechnology, Inc. Targets $50B Immunotherapy Market with New Approach - TradingView — Track All Markets
MAIA Biotechnology (NYSE: MAIA) highlights $50B immunotherapy market in press release - Stock Titan
MAIA Takes Aim at a $50B Immunotherapy Market with Breakthrough Telomere-Targeting Approach - The Manila Times
Prepare Yourself for Liftoff: MAIA Biotechnology Inc (MAIA) - setenews.com
Director Makes Bold Move with Major Stock Purchase in MAIA Biotechnology! - TipRanks
Dir Smith Buys 13,740 ($16.4K) Of Maia Biotechnology Inc [MAIA] - TradingView — Track All Markets
Can MAIA Biotechnology Inc. stock sustain revenue momentum2025 Price Targets & Real-Time Price Movement Reports - Newser
How MAIA Biotechnology Inc. stock reacts to bond yieldsWeekly Gains Summary & Free Technical Pattern Based Buy Signals - Newser
Vlad Vitoc, Maia Biotech CEO, buys $79,848 in Maia stock By Investing.com - Investing.com Australia
Vlad Vitoc, Maia Biotech CEO, buys $79,848 in Maia stock - Investing.com
Is MAIA Biotechnology Inc. stock among top earnings plays2025 Stock Rankings & Daily Chart Pattern Signals - Newser
How MAIA Biotechnology Inc. stock compares with top peersMarket Trend Summary & Fast Gain Swing Alerts - Newser
Why hedge funds are buying MAIA Biotechnology Inc. stockRisk Management & Daily Risk Controlled Trade Plans - Newser
MAIA Biotechnology Inc (MAIA) Clearly Signals Buy-Into the Stock: Don’t ignore the signals - setenews.com
How MAIA Biotechnology Inc. stock responds to policy changesTrade Analysis Report & Daily Risk Controlled Trade Plans - Newser
Will MAIA Biotechnology Inc. stock return to pre crash levels2025 Bull vs Bear & Smart Allocation Stock Reports - Newser
How MAIA Biotechnology Inc. stock compares with market leaders2025 Technical Overview & Weekly High Return Stock Forecasts - Newser
Will MAIA Biotechnology Inc. stock recover faster than industryAnalyst Upgrade & Safe Entry Zone Tips - Newser
Why MAIA Biotechnology Inc. stock could rally stronglyJuly 2025 Snapshot & Free Low Drawdown Momentum Trade Ideas - Newser
Top Executives Make Bold Moves with Major Stock Purchases at MAIA Biotechnology! - TipRanks
MAIA SEC FilingsMAIA Biotechnology Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
MAIA Biotechnology Inc Stock (MAIA) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.36%
0.21%
Cap:
|
Volume (24h):